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ARTICLE
The Stat3-Fam3a axis promotes muscle stem cell
myogenic lineage progression by inducing
mitochondrial respiration
David Sala1, Thomas J. Cunningham1,4, Michael J. Stec1, Usue Etxaniz 1, Chiara Nicoletti 1,
Alessandra Dall’Agnese1, Pier Lorenzo Puri 1,2, Gregg Duester 1, Lucia Latella2,3 & Alessandra Sacco1
Metabolic reprogramming is an active regulator of stem cell fate choices, and successful stem
cell differentiation in different compartments requires the induction of oxidative phosphor-
ylation. However, the mechanisms that promote mitochondrial respiration during stem cell
differentiation are poorly understood. Here we demonstrate that Stat3 promotes muscle stem
cell myogenic lineage progression by stimulating mitochondrial respiration in mice. We
identify Fam3a, a cytokine-like protein, as a major Stat3 downstream effector in muscle stem
cells. We demonstrate that Fam3a is required for muscle stem cell commitment and skeletal
muscle development. We show that myogenic cells secrete Fam3a, and exposure of Stat3-
ablated muscle stem cells to recombinant Fam3a in vitro and in vivo rescues their defects in
mitochondrial respiration and myogenic commitment. Together, these findings indicate that
Fam3a is a Stat3-regulated secreted factor that promotes muscle stem cell oxidative meta-
bolism and differentiation, and suggests that Fam3a is a potential tool to modulate cell fate
choices.
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Accumulating evidence indicates that metabolism is notonly a consequence of the stem cell functional status butrather an active player that regulates stem cell fate choi-
ces1. Proliferative stem cells rely on glycolysis to obtain the energy
they require, as well as to generate the necessary metabolic
intermediates to sustain their growth2,3. Next, the switch from
self-renewal towards commitment and differentiation requires the
induction of oxidative metabolism2,3. Stimulation of mitochon-
drial respiration during cell differentiation is a common feature
shared by a wide range of stem cell compartments, including
hematopoietic stem cells4,5, neuronal stem cells6,7, mesenchymal
stem cells1,8, embryonic stem cells1, and muscle stem cells
(MuSCs)2,9–12. However, the mechanisms that induce mito-
chondrial function for successful stem cell differentiation are still
poorly understood.
MuSCs are responsible for skeletal muscle formation during
development, as well as for the maintenance of tissue homeostasis
and repair during adulthood13. MuSC transition between differ-
ent functional stem cell states can be identified by the expression
of myogenic markers, which are transcription factors dynamically
expressed during MuSC myogenic lineage progression13. This
makes MuSCs a powerful tool for studying the mechanisms that
regulate stem cell fate choices. MuSCs reside in a quiescent state
in adult skeletal muscle. Upon injury, MuSCs become activated,
proliferate, and differentiate to form new myofibers and repair
the tissue14. Skeletal muscle regeneration is a very efficient pro-
cess, and temporally coordinated changes in metabolism play a
central role in regulating proper MuSC myogenic lineage pro-
gression to ensure successful muscle regeneration2,9–12,15.
Quiescent MuSCs display a low metabolic rate that mainly relies
on fatty acid oxidation2,15. MuSC activation initially induces their
glycolytic pathway in order to sustain cell proliferation2,15, and
then a switch to oxidative metabolism is required to allow further
MuSC commitment to the myogenic lineage and
differentiation2,9–12. Several pathological conditions and aging
can compromise MuSC function, alter the balance between self-
renewal and differentiation, and result in the reduction of skeletal
muscle regenerative capacity that contributes to the muscle loss
associated with these diseases16–18. Thus identifying the factors
that regulate MuSC metabolism and therefore cell fate choices is
highly relevant for therapeutic purposes.
We and others recently provided evidence that signal trans-
ducer and activator of transcription factor 3 (Stat3) regulates
MuSC fate choices during skeletal muscle regeneration19,20. Stat3
is a transcription factor that mediates the intracellular signaling of
several cytokines, including interleukin (IL)-6, leukemia inhibi-
tory factor, and Oncostatin M21. We demonstrated that Stat3
promotes MuSC progression into committed myogenic progeni-
tors and differentiation20. However, the mechanism by which
Stat3 regulates MuSC myogenic commitment is currently poorly
understood. Stat3 regulates a wide range of biological processes in
different cell types, including proliferation, migration, survival,
and metabolism21. From the metabolic point of view, Stat3 is able
to promote glycolysis or mitochondrial respiration depending on
the cellular context22–24. However, little is currently known about
the role of Stat3 in regulating MuSC metabolism.
In our study, we demonstrate that Stat3 promotes mitochon-
drial respiration during MuSC myogenic lineage progression. We
further identify Fam3a as a regulator of MuSC function that acts
as a major direct downstream effector of Stat3. Fam3a is a
cytokine-like protein shown to increase ATP production and
promote mitochondrial respiration in vascular smooth muscle
cells, neuronal cells, and hepatocytes25–27. We demonstrate that
Fam3a is required for proper MuSC myogenic lineage progres-
sion and skeletal muscle development in vivo. We further show
that Fam3a is secreted by myogenic cells and that treatment with
recombinant Fam3a rescues the reduced mitochondrial respira-
tion and defective myogenic commitment of Stat3-ablated MuSCs
both in vitro and in vivo during adult skeletal muscle repair.
Overall, this work positions the Stat3–Fam3a axis as a driver of
mitochondrial respiration during MuSC commitment and dif-
ferentiation and suggests that therapeutic interventions targeting
this axis could be utilized to promote MuSC-mediated tissue
repair.
Results
Stat3 promotes mitochondrial function in MuSCs. In order to
analyze the impact of Stat3 on MuSC gene expression during
activation, we performed RNA-seq whole-transcriptome analysis
in control and Stat3 genetically ablated MuSCs (Stat3 knockout
(KO)). To this aim, we took advantage of the Pax7-CreER driver,
as Pax7 is a transcription factor specifically expressed in MuSCs
in skeletal muscle13,20. We induced Cre-mediated Stat3 ablation
in 3-month-old Pax7-CreER;Stat3f/f male mice and control lit-
termates (Pax7-CreERWT;Stat3f/f) by tamoxifen (Tmx) treatment,
as previously reported (Fig. 1a)20. At least 2 weeks after treat-
ment, tibialis anterior muscles were injured by intramuscular
injection of barium chloride (BaCl2) to induce MuSC activation.
MuSCs were isolated from uninjured or 3 days post-injury (3 dpi)
mice by fluorescence-activated cell sorting (FACS), based on α7-
integrin and CD34 cell surface marker expression, as previously
reported (Fig. 1a)20,28. Comparison between control uninjured
and control activated MuSCs (3 dpi) showed major changes in
their transcriptome (Fig. 1b). Pathway analysis (using Gene Set
Enrichment Analysis (GSEA)29) revealed that the top enriched
pathways during activation of control (Ct) MuSCs were related to
cell cycle, protein synthesis, and mitochondrial metabolism,
consistent with previous reports (Fig. 1c, Supplementary Fig. 1a,
and Supplementary Data 1)9. Activation of Stat3 KO MuSCs also
caused extensive changes in their transcriptome (activated—3 dpi
—vs uninjured Stat3 KO MuSCs) (Fig. 1b). GSEA showed that
pathways associated with cell cycle and protein synthesis
were among the top 20 enriched pathways in activated Stat3 KO
MuSCs compared to uninjured Stat3 KO MuSCs (Fig. 1c, Sup-
plementary Fig. 1b, and Supplementary Data 2). In contrast
to what we observed during activation of control MuSCs, none
of the top 20 enriched pathways in activated Stat3 KO MuSCs
were associated with mitochondrial oxidative phosphorylation
(Fig. 1c, Supplementary Fig. 1b), suggesting that Stat3 may play a
central role in inducing mitochondrial function during MuSC
activation.
We further interrogated the data by performing pathway
analysis using the differentially expressed transcripts between
activated control and activated Stat3 KO MuSCs. GSEA identified
previously described Stat3-regulated pathways such as integrin
signaling, cytokine–cytokine receptor interaction, and Janus-
activated kinase–Stat signaling among the top enriched pathways
(Fig. 1d and Supplementary Data 3). The respiratory electron
transport pathway appeared in the top 10 differentially enriched
pathways, further suggesting that Stat3 promotes mitochondrial
function during the activation process (Fig. 1d and Supplemen-
tary Data 3). Thus we analyzed the mitochondrial respiration of
MuSCs lacking Stat3 after 3 days in culture in growth conditions.
Consistent with our pathway analysis, Stat3-ablated MuSCs
exhibited a decreased mitochondrial respiration assessed as
reduced basal and maximal oxygen consumption rate (OCR;
Fig. 1e, f). Stat3 ablation did not affect the extracellular
acidification rate (ECAR), readout for glycolysis (Fig. 1g). Overall,
this data indicates that Stat3 promotes mitochondrial respiration
during MuSC commitment to the myogenic lineage without
having a major impact on glycolysis.
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Stat3 has been shown to promote mitochondrial respiration by
translocating into the mitochondria22–24. In order to assess a
potential role of mitochondrial Stat3 during MuSC activation, we
performed immunofluorescence analysis of both total and S727
phosphorylated Stat3 in MuSCs cultured in vitro for 3 days. Stat3
S727 phosphorylation enhances its transcriptional activity in the
nucleus, and it is also required to induce the translocation of Stat3
into the mitochondria24,30,31. Both analyses showed a predomi-
nant nuclear localization for Stat3 (Supplementary Fig. 1c, d),
suggesting that nuclear Stat3 plays a major role in regulating
mitochondrial respiration during MuSC activation.
Previous studies demonstrated that mitochondrial respiration
actively promotes myogenic differentiation in cultured myo-
blasts32–36. Consistently, mitochondrial biogenesis and mito-
chondrial respiration are increased during MuSC myogenic
commitment and differentiation2,9–11,37. Thus, to further validate
that mitochondrial respiration is an important factor that
promotes myogenic progression in MuSCs, we cultured MuSCs
in vitro in growth media (GM) or differentiation media (DM) and
treated them with carbonyl cyanide 3-chlorophenylhydrazone
(CCCP) (or dimethyl sulfoxide, DMSO, as vehicle), an inhibitor
of oxidative phosphorylation, for 24 h. In both contexts, the
percentage of myogenin-positive cells was reduced in CCCP-
treated MuSCs (Supplementary Fig. 1e, f), indicating that
mitochondrial respiration is required for proper myogenic
commitment and differentiation in MuSCs.
Overall, our findings indicate that Stat3-dependent regulation
of mitochondrial respiration is a major mechanism that promotes
MuSC commitment and differentiation.
Fam3a is a downstream target of Stat3 and MyoD in MuSCs.
To identify relevant downstream targets of Stat3 that promote
MuSC mitochondrial respiration and myogenic lineage progres-
sion, we performed multiple comparisons between all the tran-
scriptomes obtained from the RNA-seq analysis (Fig. 2a). We
focused our attention on genes that were differentially expressed
during the process of activation in control MuSCs (Ct 3 dpi vs Ct),
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Fig. 1 Stat3 promotes mitochondrial function in muscle stem cells (MuSCs) during activation. a Scheme of the experimental design to obtain the samples
for RNA-seq. b Heat map of the differentially expressed genes among the different comparisons. Listed genes were differentially expressed in at least one
of the comparisons. Normalized gene RPKM (reads per kilobase of transcript per million) values were averaged within groups for the generation of the heat
map (n= 3 animals). c Pie charts showing the top 20 differentially enriched pathways (using Gene Set Enrichment Analysis (GSEA)) during the activation
of control (Pax7-CreERWT;Stat3f/f) or Stat3 KO MuSCs (Pax7-CreER;Stat3f/f mice) grouped according to their functional category. d Top 12 pathways
enriched in freshly isolated MuSCs from 3 dpi Pax7-CreER;Stat3f/f mice compared to 3 dpi MuSCs isolated from control littermates using GSEA. The red
line indicates p value= 0.05 based on the pathway analysis (GSEA). e–g Measurement of the oxygen consumption rate (OCR) and the extracellular
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Test was performed in a Seahorse XFp Analyzer. Data are represented as mean ± SEM (Student’s t test or two-way analysis of variance; *p < 0.05, ***p <
0.001, ****p < 0.0001)
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that did not respond during the activation of Stat3 KO MuSCs
(KO 3 dpi vs KO), and that were differentially expressed between
activated Stat3 KO MuSCs and activated control MuSCs (KO 3
dpi vs Ct 3 dpi). This analysis identified 63 genes (Fig. 2a). Stat3 is
primarily a transcriptional coactivator38, thus we concentrated
on the top 10 genes downregulated in activated Stat3 KO MuSCs
(KO 3 dpi) compared to activated control cells (Ct 3 dpi). Among
the significantly downregulated genes (Fig. 2b), we focused on
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Fam3a, a cytokine-like protein, as it was the only one that had
been reported to be involved in the regulation of mitochondrial
metabolism25–27.
We validated Fam3a downregulation in activated Stat3 KO
MuSCs compared to activated controls in samples different from
the RNA-seq (Fig. 2c). We further observed upregulation of
Fam3a at the mRNA level in MuSCs during myogenic
differentiation in vitro, mirroring the expression pattern of Stat3
(Fig. 2d). To investigate whether Fam3a is a direct transcriptional
target of Stat3, we performed Fam3a promoter analysis using
JASPAR39 and identified one putative Stat3-binding site 2869 bp
upstream of the transcription start site (TSS; Fig. 2e). Chromatin
immunoprecipitation (ChIP) assay in C2C12 myoblasts showed
that Stat3 is recruited to this site upon IL-6 stimulation, which
promotes Stat3 activation and translocation into the nucleus
(Fig. 2e). IL-6 treatment also caused enrichment of H3K27Ac, a
marker of active transcription, in this region (Fig. 2e). Together,
these findings indicate that Fam3a is a direct transcriptional
target of Stat3.
Further analysis of the Fam3a promoter revealed the existence
of putative MyoD-binding sites. MyoD is a transcription factor
essential for MuSC commitment to the myogenic lineage and
differentiation13, and recent work demonstrated that MyoD
regulates a set of genes responsible to sustain oxidative
metabolism in C2C12 myotubes and adult skeletal muscle10. By
analyzing previously published ChIP-seq data40, we observed
MyoD binding to the Fam3a promoter in proximity to the TSS in
C2C12 myotubes (Fig. 2f). Similarly, ChIP-seq analysis using
myogenic conversion of human IMR90 fibroblasts to the
myogenic lineage by the induction of ectopic MyoD expression
showed the recruitment of MyoD to the FAM3A promoter
(Fig. 2g). This MyoD recruitment was further increased by the
induction of differentiation in myogenically converted IMR90
fibroblasts (Fig. 2g), suggesting that MyoD regulation of Fam3a is
conserved between mouse and human species. Consistent with
ChIP-seq data, MuSCs isolated from MyoD KO mice41,42 showed
reduced Fam3a mRNA levels when cultured for 3 days in vitro
(Fig. 2h).
Finally, to further validate that Stat3 and MyoD regulate
Fam3a expression, we performed reporter assays using a
construct containing the luciferase reporter gene under the
control of the Fam3a promoter. HEK293 cells were transiently
transfected with the reporter plasmid and a Renilla encoding
plasmid (to monitor transfection efficiency), together with
plasmids encoding for Stat3 and/or MyoD (Fig. 2i). Stat3
overexpression significantly increased the transcriptional activity
of the reporter compared to control conditions, and MyoD
overexpression induced a much higher transcriptional activation
of the reporter (Fig. 2i). However, we did not observe an additive
effect when transfecting together Stat3 and MyoD coding
plasmids (Fig. 2i).
Altogether, our data indicate that both Stat3 and MyoD
directly promote Fam3a expression by binding to the respective
regulatory regions on the Fam3a promoter.
Fam3a promotes MuSC myogenic lineage progression in vitro.
To analyze the function of Fam3a in MuSCs, we performed acute
loss-of-function studies in vitro by utilizing lentiviruses expres-
sing short hairpin RNA (shRNA) against Fam3a (shFam3a) or
shRNA control (shCt). Freshly isolated MuSCs from 3-month-old
C57BL6/J male mice were placed in culture in growth conditions,
infected with lentiviruses, and after 72 h we analyzed myogenic
lineage progression. We assessed the expression levels of the
myogenic regulators Pax7 (marker of quiescent and proliferating
MuSCs), MyoD (early marker of committed progenitors), and
myogenin (late marker of committed progenitors). Fam3a mRNA
levels were efficiently reduced with shRNA treatment, and this
resulted in a reduction in myogenin mRNA (Fig. 3a). Immuno-
fluorescence analysis showed that Fam3a knockdown increased
the percentage of Pax7+MyoD− and Pax7+MyoD+ populations
and reduced the percentage of the Pax7−MyoD+ population
(Fig. 3b). We also observed a reduction in the percentage of
myogenin+ cells, consistent with our mRNA data, indicating a
reduced rate of commitment into the myogenic lineage upon
Fam3a repression (Fig. 3c). No differences in proliferation were
observed (Supplementary Fig. 2), suggesting that Fam3a specifi-
cally affects MuSC commitment. Upon induction of terminal
differentiation, MuSCs knocked down for Fam3a exhibited
impaired ability to differentiate into myosin heavy chain-positive
(MyHC+) cells, as shown by a reduced differentiation index
(Fig. 3d). Together, these findings demonstrate that Fam3a is
required for proper myogenic lineage progression in vitro and its
repression recapitulates the phenotype previously described for
Stat3 gene deletion/inhibition in MuSCs20, suggesting that Fam3a
is a relevant downstream effector of Stat3 in MuSCs.
Fam3a is required for skeletal muscle development in vivo. To
investigate the role of Fam3a in skeletal muscle in vivo, we gen-
erated a Fam3a KO mouse model by utilizing CRISPR/Cas9
genome-editing strategies (Fig. 4a). We designed a guide to spe-
cifically target exon 2 and generate frame-shift mutations that
disrupt the open reading frame (Supplementary Fig. 3a). Fam3a
contains an N-terminal secretion signal peptide (SP) followed by
the sequence corresponding to the mature protein. With this
strategy, we generated frame-shift mutations in the region
encoding for the SP and therefore disrupted the protein before
any part of the mature and active Fam3a protein is produced
(Supplementary Fig. 3a).
Fig. 2 Fam3a is a direct Stat3 and MyoD target. a Venn diagram of the overlap among the differentially expressed genes between the different comparisons
in the RNA-seq analysis. b Quantitative real-time PCR analysis of the top 10 selected candidates in the RNA-seq samples (n= 3 animals). The red line
indicates the average expression levels in control samples. c Fam3a mRNA levels in freshly isolated activated muscle stem cells (MuSCs) (3 dpi) from
Pax7-CreER;Stat3f/f mice and control littermates (different samples from RNA-seq) (n= 3–4 animals). d Gene expression analysis of MuSCs cultured in
growth media (GM) or differentiation media (DM) for 72 h (n= 3 independent experiments). e Fam3a promoter analysis using JASPAR identified one
putative Stat3-binding site. Chromatin immunoprecipitation (ChIP) assay in C2C12 myoblasts incubated in the presence or absence of interleukin-6 (100
ng/ml) to monitor the recruitment of Stat3 and the presence of histone H3 acetylated at lysine 27 (H3K27Ac) in the Fam3a promoter (n= 4 independent
experiments). f MyoD ChIP-seq signal and peak distribution on the Fam3a promoter on C2C12 myotubes. Previously published data were used for the
analysis40. g MyoD ChIP-seq signal distribution and peaks on the FAM3A promoter on IMR90-derived myoblasts and myotubes. h Fam3a mRNA levels in
wild type and MyoD−/− MuSCs cultured in growth conditions for 72 h (n= 4 independent experiments). i Reporter assay in HEK293 cells transfected
with plasmids encoding Stat3, MyoD, and/or an empty vector as control, together with the reporter vector containing the luciferase reporter gene under
the control of the Fam3a promoter (n= 12 independent experiments). Data are represented as mean ± SEM (Student’s t test; *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001)
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We injected the guide and Cas9 mRNAs into zygotes and
assessed skeletal muscle development in E15 embryos and P0
pups (Fig. 4a). As Fam3a is an X chromosome-encoded gene, we
focused our studies on males. DNA sequencing of the 5 Fam3a
KO embryos analyzed in this study showed a frame-shift
mutation in exon 2 (Supplementary Fig. 3b). Fam3a KO embryos
exhibited significantly smaller hind limb muscles, shown by the
reduced embryonic myosin heavy chain (eMyHC) area (Fig. 4b),
as well as a reduction in the number of myogenin+ nuclei (Fig. 4c,
d), compared to controls. We further analyzed Fam3a KO male
mice at birth (P0). The three Fam3a KO pups used in this study
displayed a frame-shift mutation in exon 2 (Supplementary
Fig. 3b). Also in this context, we observed a reduction in eMyHC
area and an accumulation of uncommitted MuSCs (assessed as
increased number of Pax7+ cells) (Fig. 4e, f). Additionally,
laminin was also more disrupted in Fam3a KO pups compared to
controls (Fig. 4e, f). These findings are consistent with a role of
Fam3a in promoting myogenic commitment and muscle
differentiation during development, with its ablation leading to
a deficient MuSC progression into the myogenic lineage in vivo
and compromised skeletal muscle formation.
To assess whether the reduction in muscle mass was
maintained in adulthood, we analyzed body and tissue weights
from 3-month-old wild-type (WT) and Fam3a KO male mice.
Indeed, Fam3a deletion resulted in decreased body weight,
together with a significant reduction in the gastrocnemius,
quadriceps, and heart weights (Supplementary Fig. 4). We did
not observe differences in the weight of other tissues such as liver,
epididymal white adipose tissue, spleen, or kidneys (Supplemen-
tary Fig. 4). Together, this data indicates that Fam3a ablation
causes a reduction in skeletal muscle mass during development
that is maintained in adulthood.
Fam3a is known to induce mitochondrial respiration in several
cell types25–27. Thus we assessed whether Fam3a also promotes
mitochondrial function in MuSCs. To this aim, we measured the
mitochondrial respiration in WT and Fam3a KO MuSCs cultured
in growth conditions for 3 days. Fam3a genetic deletion reduced
both basal and maximal mitochondrial respiration in MuSCs
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Fig. 3 Fam3a promotes muscle stem cell (MuSC) myogenic lineage progression in vitro. a Gene expression analysis of MuSCs infected with lentiviruses
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without affecting glycolysis (Supplementary Fig. 5a–c). This
reduction in mitochondrial oxygen consumption was not due to
reduced mitochondrial content or changes in the expression of
Pgc1a or different subunits of the electron transport chain in
MuSCs (Supplementary Fig. 5d–f). Consistent with this data,
Fam3a overexpression in C2C12 myoblasts did not affect the
expression of Pgc1a or different subunits of the electron transport
chain at the mRNA or protein level (Supplementary Fig. 5g–j).
Together, this data demonstrates that Fam3a does not promote
mitochondrial respiration by regulating mitochondrial content,
biogenesis, or the expression of the electron transport chain
complexes in myogenic cells, suggesting that alternative mole-
cular mechanisms are taking place.
Overall, our data indicate that Fam3a is required for proper
skeletal muscle development by stimulating mitochondrial
respiration in MuSCs and promoting their myogenic lineage
progression.
Fam3a is secreted by myogenic cells. Fam3a protein sequence
analysis using LocTree343 predicted that Fam3a is a secreted
protein (Supplementary Fig. 6a). However, previous reports
indicated a localization of Fam3a in the mitochondria25–27. To
strengthen our prediction, we used two additional softwares that
predict protein localization: TargetP44 and MitoFates45. TargetP
is a software that predicts protein localization by analyzing the
presence of N-terminal presequences containing mitochondrial
targeting peptides or secretory SPs44. TargetP analysis of the
Fam3a protein sequence also predicted that Fam3a is a secreted
protein, while it correctly predicted that the protein Citrate
Synthase was mitochondrial (Supplementary Fig. 6a). Finally, we
used MitoFates as software that analyzes the presence of N-
terminal mitochondrial targeting signals and their cleavage
sites45. Consistent with the previous predictions, Fam3a did not
contain any mitochondrial localization presequence while it was
identified in Citrate Synthase (Supplementary Fig. 6b). Overall,
the analysis of the Fam3a protein sequence using three different
softwares indicated that Fam3a is a secreted protein that lacks a
mitochondrial localization signal.
To directly investigate the subcellular localization of Fam3a in
muscle cells, we performed colocalization studies in transiently
transfected C2C12 myoblasts with a construct expressing
Fam3a-Myc-Flag. In order to label Golgi, endoplasmic reticu-
lum (ER), and mitochondria, we used the markers GM-130,
KDEL, and Tomm20, respectively. In accordance with pre-
viously published studies, these markers were specific for each
compartment as they presented no or minimal colocalization
among them (Supplementary Fig. 6c, d)46–49. Consistent with
our Fam3a localization predictions, we did not detect coloca-
lization between exogenous Fam3a and mitochondria 48 h after
transfection (Supplementary Fig. 6d, e). Instead, exogenous
Fam3a colocalized with GM-130, marker of cis-Golgi (Fig. 5a
and Supplementary Fig. 6d). Upon treatment with the secretion
inhibitor monensin, Fam3a-Myc-Flag strongly colocalized with
the ER, as shown by colocalization with KDEL (Fig. 5b and
Supplementary Fig. 6d). Western blot analysis detected accu-
mulation of Fam3a-Myc-Flag within C2C12 myoblasts upon
monensin treatment (Fig. 5c, d). Finally, we observed the
presence of Fam3a-Myc-Flag in the media of transfected cells
(Fig. 5e). Together, these findings demonstrate that Fam3a is
secreted by myogenic cells.
Fam3a is a ubiquitously expressed cytokine-like protein50,
suggesting that it could also be produced by other muscle-
resident cell types known to promote MuSC myogenic lineage
progression, such as fibroadipogenic progenitors (FAPs) or
macrophages (MPs)51–53. To address this question, we performed
quantitative real-time PCR (qPCR) analysis in muscle-resident
cell types isolated from two highly myogenic contexts: postnatal
muscle growth and adult tissue regeneration (Supplementary
Fig. 7). During postnatal growth, we isolated mononucleated cells
(MuSCs, MPs, and FAPs) and myofibers from P15 pups and 3-
month-old C57BL6/J mice (Fig. 5f and Supplementary Fig. 7).
Our results show that myofibers contain much higher levels of
Fam3a transcript than mononucleated cells (Fig. 5f), suggesting
that myofibers are the main producers of Fam3a in the skeletal
muscle during postnatal growth and also in the adult skeletal
muscle.
To assess Fam3a expression during adult skeletal muscle
regeneration, we isolated mononucleated cells from 3-month-
old male mice at three different time points: uninjured, 3 dpi,
and 7 dpi (Fig. 5g and Supplementary Fig. 7). Three days after
injury, both MPs and FAPs are the highest Fam3a-expressing
cells at the population level (Fig. 5g). Seven days after injury,
FAPs are the main Fam3a-expressing cells in the tissue (Fig. 5g),
suggesting that FAPs may be a relevant source of Fam3a during
skeletal muscle regeneration. Overall, our data suggest that
Fam3a is a secreted factor that may mediate the coordination of
the different muscle-resident cell types during myogenesis.
Fam3a rescues myogenic commitment of Stat3 KO MuSCs. To
evaluate whether the secretion of Fam3a is relevant for its role on
MuSC function, we performed rescue studies by adding Fam3a
recombinant protein into the culture media. First, we used
shRNA-mediated Fam3a loss of function (shFam3a). Addition of
recombinant Fam3a increased the percentage of myogenin+ cells
in shFam3a MuSCs cultured in both GM and DM (Fig. 6a and
Supplementary Fig. 8a). Treatment did not affect the percentage
of myogenin+ cells in control MuSCs (shCt) (Fig. 6a and Sup-
plementary Fig. 8a), suggesting that control cells produce suffi-
cient Fam3a levels to sustain their myogenic lineage progression
and differentiation in culture. In a second set of experiments, we
asked whether incubation with recombinant Fam3a was sufficient
to rescue the defects in myogenic lineage progression and dif-
ferentiation of Stat3 KO MuSCs in vitro. Indeed, addition of
Fam3a protein into the media of Stat3 KO MuSCs rescued the
percentage of myogenin+ cells up to the levels of control cells
when cultured in GM (Fig. 6b), validating that it is a relevant
Stat3 downstream effector. Treatment with recombinant Fam3a
was not sufficient to rescue the deficit in myogenic differentiation
of Stat3 KO MuSCs, suggesting that other downstream targets of
Stat3 also play a relevant role in differentiation conditions
(Supplementary Fig. 8b). Treatment did not affect the percentage
of myogenin+ cells in control MuSCs (Fig. 6b and Supplementary
Fig. 8b).
Our data demonstrate that both Stat3 and Fam3a promote
mitochondrial function during MuSC activation. Thus we
assessed whether treatment with Fam3a could also rescue the
reduced mitochondrial respiration observed in Stat3 KO MuSCs.
Incubation of Stat3 KO MuSCs with Fam3a recombinant
protein for 72 h in growth conditions increased their basal and
maximal mitochondrial respiration to levels similar to control
cells (Fig. 6c, d) without affecting the ECAR (Fig. 6e). Consistent
with our previous data, treatment with recombinant Fam3a
did not affect mitochondrial respiration in control MuSCs
(Supplementary Fig. 8c–e).
Finally, to demonstrate that Fam3a secretion also plays a
relevant role during adult skeletal muscle regeneration in vivo, we
performed rescue studies using Tmx-treated 4-month-old Pax7-
CreER;Stat3f/f male mice and control littermates. Tibialis anterior
muscles of these mice were injured with barium chloride, and
1 day after injury we delivered Fam3a recombinant protein (or
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vehicle as control) by intramuscular injection (Fig. 6f). Vehicle-
treated muscles from Pax7-CreER;Stat3f/f mice displayed a higher
number of Pax7+ cells 6 days after the initial injury compared to
vehicle-treated muscles from control animals, as previously
shown (Fig. 6g)20. Strikingly, treatment with recombinant Fam3a
of Pax7-CreER;Stat3f/f injured muscles normalized the number of
Pax7+ cells to the levels of control mice (Fig. 6g). Moreover,
treatment with recombinant Fam3a significantly increased the
number of myogenin+ cells in injured Pax7-CreER;Stat3f/f
muscles (Fig. 6h). Overall, this data indicates that Fama3a is a
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major downstream effector of Stat3 in MuSCs that promotes
myogenic commitment in vivo.
Discussion
Understanding the mechanisms that regulate stem cell fate
choices is one of the goals of regenerative medicine in order to
develop efficient therapeutic approaches, and stem cell metabolic
reprogramming is emerging as a strategy with the potential to
improve tissue repair1,2. Common to several stem cell compart-
ments, MuSC commitment and differentiation requires the
induction of oxidative metabolism2,3,9–12. For instance, the
induction of mitochondrial function is required for neuronal
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differentiation6,7, the osteogenic and adipogenic differentiation of
mesenchymal stem cells1,8, myeloid differentiation of hemato-
poietic stem cells4,5, and cardiac differentiation54.
Here we used MuSCs as a model to study the factors that
promote mitochondrial activity during stem cell differentiation.
Previous studies performed in cultured myoblasts proved that
mitochondrial respiration promotes myogenic differentiation32–36.
Consistent with this data, we have shown that inhibition of oxi-
dative phosphorylation impairs MuSC myogenic commitment,
and we have characterized the Stat3–Fam3a axis as an inducer of
mitochondrial respiration that promotes myogenic differentiation.
Indeed, transcriptomic analysis of early activated Stat3-ablated
MuSCs showed reduced mitochondrial respiration before any
alteration in the expression of the myogenic markers occur, sug-
gesting that the defects in mitochondrial function precedes the
impairment in myogenic commitment of Stat3 KO MuSCs. These
findings further demonstrate that Stat3 translates microenviron-
mental cues to changes in stem cell metabolism.
Stat3 has been previously shown to regulate cell metabolism in
a complex manner depending on posttranslational modifications,
cellular localization, and cell type, with the current view that
nuclear Stat3 promotes glycolysis, while mitochondrial Stat3
promotes oxidative phosphorylation22–24. Our data show that
nuclear Stat3 can also promote mitochondrial function by reg-
ulating the expression of nuclear-encoded genes in MuSCs.
Indeed, here we provide evidence that Stat3 directly promotes the
expression of the secreted protein Fam3a as one downstream
target that increases mitochondrial respiration in MuSCs. We and
others previously showed that Stat3 induces MuSC commitment
by regulating MyoD expression19,20, and a recent report indicated
that MyoD is required to maintain the respiratory capacity of the
mitochondria in C2C12 myotubes and adult skeletal muscles by
regulating the expression of nuclear-encoded genes10. Here we
demonstrate that both Stat3 and MyoD are able to induce Fam3a
expression in myogenic cells by directly binding to its promoter.
Additionally, ChIP-seq data showed that MyoD binds to the
Fam3a promoter in both mouse and human models of myogenic
differentiation, suggesting that the regulation of Fam3a expres-
sion is conserved between species. Overall, this data points to the
existence of a regulatory network, which includes Stat3 and
MyoD, that aims at progressively increasing Fam3a expression
and oxidative metabolism in myogenic progenitors to ensure
efficient differentiation.
Fam3a biological function is still poorly understood and a
potential role of Fam3a in the skeletal muscle has not been pre-
viously reported. Here we show that Fam3a is required for proper
MuSC myogenic lineage progression and skeletal muscle devel-
opment in vivo. Indeed, our data suggest that Fam3a genetic
ablation affects the dynamics of the myogenic progenitors during
development. Specifically, Fam3a absence results in reduced
number of myogenin+ cells and increased number of
uncommitted MuSCs (Pax7+), suggesting that there is a delay in
the myogenic lineage progression of MuSCs during the skeletal
muscle development of Fam3a-null mice. Interestingly, our stu-
dies showed that partial Fam3a loss of function is sufficient to
impair MuSC myogenic commitment, suggesting that there is a
requirement of a minimum level of Fam3a to ensure proper
myogenic lineage progression.
We further demonstrate that Fam3a is a cytokine-like protein
secreted by myogenic cells. Our data show that myofibers are the
major expressers of Fam3a in the skeletal muscle. This is con-
sistent with the progressive increase in Fam3a expression during
myogenic differentiation and suggests that the Fam3a secreted by
myogenic cells plays a major role during skeletal muscle growth
and regeneration by acting in a paracrine and/or autocrine
manner. We observed that Fam3a is also expressed by other
muscle-resident cells such as FAPs and MPs. FAPs and MPs are
known to support myogenic lineage progression51–53, which
suggests that Fam3a could also be produced by these other cell
types and contribute to the differentiation of myogenic progeni-
tors. We believe that this could be especially relevant to promote
tissue repair in the context of adult skeletal muscle regeneration,
where there is a transient increase in the abundance of MPs and
FAPs in the skeletal muscle. However, during muscle tissue
growth and homeostasis, myogenic cells are the major producers
of Fam3a in the tissue microenvironment.
Consistent with previous reports showing that Fam3a stimu-
lates mitochondrial respiration in hepatocytes, neuronal cells, and
vascular smooth muscle cells25–27, we demonstrate that Fam3a
plays a similar role in MuSCs. Genetic ablation of Fam3a reduces
MuSC mitochondrial respiration, while treatment with recombi-
nant Fam3a rescues the defects in mitochondrial respiration in
Stat3-ablated MuSCs. Previous studies showed that inhibition of
mitochondrial respiration in myogenic cells specifically compro-
mises the induction of myogenin expression during myogenic
differentiation and does not affect the expression of other myo-
genic markers such as MyoD34–36, which is equivalent to the
phenotype we observe in our Fam3a loss-of-function studies. We
provided evidence that Fam3a does not affect mitochondrial
biogenesis, content, or the expression levels of different subunits
of the electron transport chain complexes. However, the mole-
cular mechanism by which Fam3a stimulates mitochondrial
respiration in MuSCs is still unknown. Fam3a overexpression has
been reported to induce Akt and AMPK activation in different
cell types25–27, and as both pathways have been shown to regulate
MuSC metabolism and to promote myogenic commitment and
differentiation9,11,55, future studies should characterize the rela-
tionship between Fam3a and these signaling networks in MuSCs.
Overall, our findings indicate that Fam3a is a Stat3 and MyoD
downstream target that promotes mitochondrial respiration and
differentiation of MuSCs. Identification and characterization of
regulators of MuSC metabolism is relevant for therapeutic
Fig. 6 Fam3a rescues impaired commitment of Stat3 knockout (KO) muscle stem cells (MuSCs) in vitro and in vivo. a Immunofluorescence analysis and
quantification of myogenin expression in MuSCs infected with shCt or shFam3a coding lentiviruses and cultured in growth conditions for 72 h in the
presence or absence of recombinant Fam3a (1000 ng/ml) (n= 3 independent experiments). Scale bar 25 μm. b Immunofluorescence analysis and
quantification of myogenin expression in control and Stat3 KO MuSCs cultured in growth conditions for 72 h in the presence or absence of recombinant
Fam3a (1000 ng/ml) (n= 5 independent experiments). Scale bar 25 μm. c–e Measurement of the oxygen consumption rate (OCR) and the extracellular
acidification rate (ECAR) of Stat3 KO MuSCs cultured in growth conditions for 3 days in the presence or absence of recombinant Fam3a (1000 ng/ml)
(n= 5 independent experiments). The Cell Mito Stress Test was performed using the Seahorse XFp Analyzer. f Scheme of the experimental design for the
intramuscular Fam3a treatment in vivo. g, h Immunofluorescence analysis and quantification of Pax7- and myogenin-positive cells in transversal sections of
the tibialis anterior muscles of Pax7-CreERWT;Stat3f/f and Pax7-CreER;Stat3f/f male mice 6 days after barium chloride injury. Vehicle or 1 μg of Fam3a
recombinant protein was injected intramuscularly 1 day after inducing injury (n= 3–4 animals). Scale bar 25 μm. Data are represented as mean ± SEM
(Student’s t test or two-way analysis of variance; *p < 0.05, **p < 0.01, ****p < 0.0001)
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purposes as they can be utilized to modulate the balance between
MuSC self-renewal and differentiation, improve tissue repair in
diseased conditions with deficient skeletal muscle regenerative
capacity, and ameliorate muscle wasting.
Methods
Animal procedures. All protocols were approved by the Sanford Burnham Prebys
Medical Discovery Institute Animal Care and Use Committee and by the Italian
Ministry of Health, the National Institute of Health (IIS), the Santa Lucia Foun-
dation (Rome) Animal Care and Use Committee. The study is compliant with all
relevant ethical regulations regarding animal research. Mice were housed according
to institutional guidelines, in a controlled environment at a temperature of 22 °C ±
1 °C, under a 12-h dark–light period and provided with standard chow diet and
water ad libitum. Male Pax7-CreER;Stat3f/f mice and control Pax7-CreERWT;Stat3f/f
littermates (between 3- and 7-month-old) were used. Pax7-CreER;Stat3f/f mice
were maintained in C57BL/6J background20. Fam3a KO mice were generated in a
C57BL/6J background, and F0 generation E15 male embryos and P0 male pups
were analyzed. Adult 3-month-old Fam3a KO mice were also used in this study.
MyoD−/− mice were maintained in a B6;129 genetic background41,42, and 3-
month-old male mice were used. Young (3–4-month-old) male C57BL/6J mice
were purchased from Jackson Laboratories. Day 15 C57BL6/J pups were obtained
from the C57BL/6J colony maintained by the SBP Animal Facility. Mice within the
same genotype were randomized in all the studies.
Three-month-old Pax7-CreER;Stat3f/f mice and control Pax7-CreERWT;Stat3f/f
littermates were treated with Tmx (i.p., 0.1 mg/g body weight, cat.#T5648, Sigma)
for 5 consecutive days. Tmx was resuspended in corn oil. Experiments were
performed after at least 2 weeks from the last Tmx injection (mice were between 4-
and 7-month-old).
To induce skeletal muscle injury, mice were anesthetized by 1–4% L/min O2
isofluorane (cat.#502017, MWI Vet Supply) inhalation, and tibialis anterior
muscles were injured by intramuscular injection of 50 μl of barium chloride (1.2%
w/v, cat.#202738, Sigma). Tissues were harvested at the indicated time points for
FACS or histological analysis.
For the Fam3a in vivo treatment, 1 µg of Fam3a recombinant protein (or vehicle
as control) was injected intramuscularly into the tibialis anterior muscles of the
mice 1 day after inducing barium chloride injury. Histological analysis was
performed 6 days after the initial injury.
Generation of Fam3a KO mice. CRISPR/Cas9 gene editing to generate Fam3a
mutant embryos was performed. A single guide RNA (sgRNA) to target inside exon
2 was designed using Guidescan.com to ensure maximum specificity and cutting
efficiency (sgRNA sequence: CTAGTCACCATCCTCCTAGG). DNA template for
the sgRNA was generated by PCR amplification (Q5 DNA Polymerase; cat.
#M0491S, New England BioLabs) of ssDNA ultramer oligonucleotide (Integrated
DNA Technologies); sgRNA was transcribed from this template using the HiScribe
T7 High Yield RNA Synthesis Kit (cat.#E2040S, New England Biolabs), treated
with DNAse I (cat.#M0303S, New England Biolabs), and purified using the
Megaclear Kit (cat.#AM1908, Invitrogen). For mouse zygote injections, 50 ng/µl
Cas9 mRNA (Life Technologies) and 20 ng/µl sgRNA were combined in IDTE
buffer (IDT). Fertilized oocytes were collected from 3- to 4-week-old superovulated
C57BL/6J females (prepared by injecting 5 IU each of pregnant mare serum
gonadotropin and human chorionic gonadotropin (Sigma)), then transferred into
M2 medium (Millipore), and injected with the Cas9 mRNA/sgRNA solution into
the cytoplasm. Injected embryos were then re-implanted into recipient pseudo-
pregnant ICR female mice. Some of the implanted females were sacrificed 15 days
after re-implantation for E15 embryos analysis. Tail DNA was collected for gen-
otyping by PCR (cat.#Bio-21126, Bioline MyTaq Extract Kit) (see Supplementary
Table 1 for primer sequences) followed by Sanger sequencing to assess for muta-
tions. Fam3a KO mice that displayed in-frame indels were excluded from the study.
Genotyping to identify the gender of the embryos and P0 pups was performed by
amplifying fragments with different lengths from the X and Y chromosomes56.
Mononucleated cell isolation from adult skeletal muscle. Mononucleated cells
were isolated from tibialis anterior, gastrocnemius, and quadriceps muscles by
FACS57. Tissues were minced and subjected to an initial enzymatic digestion (700
units/ml collagenase, cat.#17101015, Life Technologies) for 90 min. After a second
enzymatic digestion (100 units/ml collagenase and 2 units/ml dispase (cat.
#17105041, Life Technologies)) for 30 min, the cell suspension was filtered through
a 70-μm nylon filter.
For the experiments where only MuSCs were isolated, samples were then
incubated with the following biotinylated rat antibodies: CD45 (clone 30-F11, cat.
#553078, BD Biosciences, 1/400), CD11b (cat.#553309, BD Biosciences, 1/150),
CD31 (cat.#5011513, eBioscience, 1/150), and Sca1 (clone E13-161.7, cat.# 553334,
BD Biosciences, 1/150). Streptavidin microbeads (cat.#130-048-101, Miltenyi) were
then added to the cells together with the α7-integrin–phycoerythrin antibody
(clone R2F2, cat.#67-0010-05, Ablab, 1/150), CD34–Alexa647 antibody (clone
RAM34, cat.#560230, BD Biosciences, 1/50), and Streptavidin APC-Cy7 (cat.
#554063, BD Biosciences, 1/150). Magnetic depletion of biotin-positive cells was
performed before fractionating the (CD45−CD11b−CD31−Sca1−) α7-integrin
+CD34+ population by flow cytometry (BD FACS Aria) and purity check.
For the experiments isolating the three populations of mononucleated cells
(MuSCs, MPs, FAPs), samples were incubated with the following antibodies: CD45
(clone 30-F11, cat.#553078, BD Biosciences, 1/400), CD11b (cat.#553309, BD
Biosciences, 1/150), CD31 (cat.#5011513, eBioscience, 1/150), F4/80-FITC (cat.
#114801-82, eBioscience, 1/150), α7-integrin–phycoerythrin antibody (clone R2F2,
cat.#67-0010-05, Ablab, 1/150), CD34–Alexa647 antibody (clone RAM34, cat.
#560230, BD Biosciences, 1/50), Sca1-Pacific Blue (clone E13-161.7, cat.# 122520,
Biolegend, 1/150), and Streptavidin APC-Cy7 (cat.#554063, BD Biosciences, 1/
150). The following populations were isolated by flow cytometry (BD FACS Aria):
MuSCs (CD45−CD11b−CD31−Sca1−α7-integrin+CD34+) MPs (CD45+CD11b
+CD31+F4/80+) and FAPs (CD45−CD11b−CD31−Sca1+α7-integrin−CD34+).
Furthermore, for the two time points after injury, we isolated two different
populations of MuSCs: CD45−CD11b−CD31−Sca1−α7-integrin+CD34+ cells and
CD45−CD11b−CD31−Sca1−α7-integrin+CD34− progenitors.
Mononucleated cell isolation from P15 pup skeletal muscle. MuSCs, MPs, and
FAPs were isolated from the hind limb skeletal muscles of 15 days old (P15)
C57BL6/J pups by FACS58. Briefly, hind limb muscles were harvested, minced, and
enzymatically digested for 45–50 min (45 units/ml Collagenase A, Roche; 2.4 units/
ml Dispase I, Roche) for 45–50 min at 37 °C in a rotating water bath. Next, cell
suspension was filtered through 70-µm nylon filter and incubated with the primary
antibodies listed in the previous section. After incubation, cells were washed,
resuspended in FACS Buffer, and filtered through 40-µm strain filter. Flow cyto-
metry (BD FACS Aria) was performed to isolate MuSCs (CD45−CD11b−CD31−
Sca1−α7-integrin+CD34+), MPs (CD45+CD11b+CD31+F4/80+), and FAPs
(CD45−CD11b−CD31−Sca1+α7-integrin−CD34+). FACS data were analyzed in
FlowJo (version 10.0.4; FlowJo LLC).
Single myofiber isolation. Single myofibers were isolated from the gastrocnemius/
soleus muscles from adult and P15 mice59. In brief, muscles were harvested and
subjected to enzymatic dissociation (700 U/ml collagenase type II, Gibco cat.
#17101-015) for 60 min at 37 °C in a shaking water bath. Dissociated single
myofibers were manually collected under a dissection microscope and gently
washed three times with Dulbecco’s modified Eagle’s medium (DMEM) containing
10% horse serum to remove debris and interstitial cells. Single myofibers were then
pooled and lysed with QIAzol lysis reagent (Qiagen cat.#79306) for subsequent
RNA extraction and qPCR analysis.
RNA sequencing. MuSCs were isolated from Pax7-CreER;Stat3f/f and Pax7-
CreERWT;Stat3f/f mice. Total RNA was isolated according to the manufacturer’s
instructions with DNAse digestion (cat.#217084, Qiagen). RNA quality was verified
by the Agilent 2100 Bioanalyzer. RNA-seq was performed using an Illumina HiSeq
2500 instrument by the Analytical Genomics and Bioinformatics Core Facility
(SBP, Lake Nona). Up to 1 µg of total RNA was used to prepare standard Illumina
single read True-seq libraries and library quality was controlled by using Agilent
Bioanalyzer, Qubit, and KAPA qPCR. The KAPA primers target Illumina P5 and
P7 flow-cell oligo sequences provide an accurate indication of the quantity of a
given library. Spiking control PhiX DNA was applied to monitor the run metrix.
The Illumina machine built-in software provided read quality scores (Q > 30). The
raw reads (FastQ files) from Illumina HiSeq2500 were aligned to the mouse gen-
ome (mm10 assembly) using TopHat2 splice-aware aligner with RefSeq annota-
tions and the “—no-novel- juncs” option60. Ambiguous reads that mapped to >1
region in the genome and reads with MAPQ score <10 were removed.
Expectation–Maximization approach was used to estimate transcript abundance61,
and the raw read counts and normalized read counts (RPKM: reads per kilobase
per million mapped reads) were obtained62. Normalization between samples was
also performed63. Gene differential expression analysis was done using the gen-
eralized linear model likelihood ratio test implemented in the edgeR software64.
Transcripts detected in at least one sample (RPKM > 1), fold change >2, and
p value < 0.05 were considered as significant differential expression. GSEA with
pre-ranked method was used to perform pathway analysis29. Normalized gene
RPKM values were averaged within groups for heat map generation.
Cell culture procedures. All cells were cultured in incubators at 37 °C and 5%
CO2. Freshly isolated MuSCs were plated on tissue culture plates coated with
laminin (cat.#11243217001, Roche) and maintained in GM (45% DMEM, 40% F10,
15% fetal bovine serum (FBS)). Myogenic differentiation was induced with DMEM
and 2% horse serum for 2 or 3 days. MuSC proliferation was measured by 5-
ethynyl-2′-deoxyuridine (EdU) incorporation (5 ng/µl, cat.#A10044, Life Tech-
nologies) for 4 h at the end of the culture. MuSCs were treated with CCCP (12.5
μM when cultured in GM and 5 μM when cultured in DM) (cat.#C2759, Sigma) for
24 h when indicated. MuSCs were treated with recombinant FAM3A (1000 ng/ml,
cat.#TP303495, OriGene) for 72 h when indicated.
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C2C12 myogenic cells were obtained from ATCC (crl-1772) and we did not
perform further authentication. C2C12 cells were grown in High Glucose DMEM
supplemented with FBS (10%). Myogenic differentiation was induced with High
Glucose DMEM and 2% horse serum for 5 days. C2C12 myogenic cells were
treated with recombinant IL-6 (100 ng/ml, cat.# 216-16, Peprotech) for 24 h when
indicated. C2C12 cells were treated with 200 μM Monensin (cat.#M5273, Sigma)
for 4 h when indicated.
HEK-293 cells were obtained from ATCC (crl-1573) and grown in High
Glucose DMEM supplemented with 10% FBS. We did not perform further
authentication.
IMR90 cells were obtained from Coriell (I90-10) and grown in Eagle’s minimal
essential medium (EMEM) (ATCC) supplemented with 10% FBS. We did not
perform further authentication.
Immunofluorescence in muscle sections. Muscle tissues were dissected and
embedded in optimal cutting temperature compound (cat.#4583; Tissue-Tek;
Sakura Finetek), snap-frozen in isobutane and liquid nitrogen, and sectioned at 10-
μm thickness. Muscle sections were fixed with 4% paraformaldehyde (PFA) for 15
min. For eMyHC staining, sections were fixed with acetone for 10 min at −20 °C.
After three washes with phosphate-buffered saline (PBS) for 10 min, sections were
permeabilized and blocked in 20% Goat Serum (cat.#16210-072, Life technologies)
and 0.3% Triton (cat.#H5142, Promega) in PBS for 1 h. For Pax7 staining, antigen
retrieval was performed and sections were post fixed with 4% PFA. Incubation with
the primary antibodies was performed overnight (O/N) at room temperature (RT).
The following primary antibodies were used: mouse anti-Pax7 (cat.#Pax7-c,
Developmental Studies Hybridoma Bank (DSHB), 1/100 dilution), rabbit anti-
Laminin A1 (cat.#L9393, Sigma, 1/100 dilution), rat anti-laminin B2 (cat.#05-206,
Millipore, 1/50 dilution), mouse anti-myogenin (cat.#556358, BD Biosciences, 1/
100), and mouse anti-eMyHC (cat.#F1.652, DSHB, 1/100). Alexa-conjugated sec-
ondary antibodies (Invitrogen, 1/250 dilution) were used. Nuclei were counter-
stained with Hoechst 33342 (cat.#H3570, Invitrogen). Images of muscle transverse
sections were acquired using: the Inverted IX81 Olympus Compound Fluorescence
Microscope with ×10 or ×20 magnification lenses, Color/monochrome cooled CCD
camera - Spot RT3, and MetaMorph 7.11 Software (UIC, Molecular Devices) or the
Leica TCS SP8 confocal microscope with the ×20 magnification lens and LAS X
software. Images were composed and edited using Photoshop CS6 (Adobe).
Immunofluorescence in cultured cells. Cells were fixed with 1.5% PFA for 15 min
and washed three times with PBS for 10 min. For Stat3 and S727 pStat3 stainings,
cells were fixed with 4% PFA for 15 min and with cold methanol (−20 °C) for 10
min. Next, cells were permeabilized and blocked in 20% Goat Serum (cat.#16210-
072, Life Technologies) and 0.3% Triton (cat.#H5142, Promega) in PBS for 1 h.
Incubation with the primary antibodies was performed O/N at RT. The following
primary antibodies were used: mouse anti-Pax7 (cat.#Pax7-c, Developmental
Studies Hybridoma Bank (DSHB), 1/100 dilution), rabbit anti-Myod1 (cat.#sc760,
Santa Cruz, 1/30 dilution), mouse anti-myogenin (cat.#556358, BD Biosciences, 1/
100 dilution), mouse anti-Myosin Heavy Chain (cat.#Mf20-c, DSHB,1/50 dilution),
rabbit anti-Ki67 (cat.#ab15580, Abcam, 1/100 dilution), rabbit anti-Myc tag (cat.
#ab9106, Abcam, 1/100 dilution), rat anti-KDEL (cat.#ab50601, Abcam, 1/150
dilution), rabbit anti-Tomm20 (cat.# NBP1-81556, Novus Biologicals, 1/100 dilu-
tion), mouse anti-Flag (cat.#F3165, Sigma, 1/500 dilution), mouse anti-GM130
(cat.#610823, BD Biosciences, 1/150 dilution), mouse anti-Stat3 (cat.#9139, Cell
Signaling, 1/100 dilution), and rabbit anti-pStat3 (S727) (cat.#9134, Cell Signaling,
1/50 dilution). Alexa-conjugated secondary antibodies (Invitrogen, 1/250 dilution)
were used. Nuclei were counterstained with Hoechst 33342 (cat.#H3570, Invitro-
gen). EdU staining was performed following the manufacturer’s instructions (cat.
#C10340, Life Technologies). Images of cultured cells were acquired using the
Inverted IX81 Olympus Compound Fluorescence Microscope with ×10 or ×20
magnification lenses, Color/monochrome cooled CCD camera - Spot RT3, and
MetaMorph 7.11 Software (UIC, Molecular Devices). For the subcellular localiza-
tion studies, the Leica TCS SP8 confocal microscope with the ×20 and ×40 mag-
nification lens and LAS X software was used. For colocalization studies, Pearson’s
correlation coefficient was calculated using Coloc2 (with Costes threshold cor-
rection) in Fiji65. Corrected Total Cell Fluorescence for Tomm20 was calculated
using Fiji65. Images were composed and edited using Photoshop CS6 (Adobe).
Lentiviral infection. Lentiviruses were purchased from the MISSION shRNA
library (Sigma) as part of an agreement with the Sanford Consortium of Regen-
erative Medicine. Tissue culture plates were coated with laminin (20 μg/ml) (cat.
#11243217001, Roche) for 45 min at 37 °C, followed by RetroNectin (15 μg/ml)
(cat.#T100A, Takara) for 2 h at RT. Plated MuSCs were infected with lentiviruses
coding for an shFam3a or non-mammalian control (shCt) in GM supplemented
with 8 ng/ml polybrene (cat.#TR-1003-6, Millipore) O/N at 37 °C and 5% CO2.
Transient transfection. C2C12 cells were transfected with a Fam3a overexpression
plasmid (cat.#MR202771, OriGene) and/or a green fluorescent protein over-
expression plasmid (cat.#13031, Addgene) using LipofectamineTM 3000 (cat.
#L3000001, Invitrogen) and following the manufacturer’s instructions. Cells were
transfected with 1 μg DNA.
IMR90 myogenic conversion. IMR90 cells were electroporated using the Neon
Transfection System (Invitrogen, MPK5000, MPK10025) with helper plasmid and
epB-Puro-TT containing or not murine Myod1 cDNA. Cells were then selected
with 2 μg/ml of puromycin dihydrochloride (MP Bio). When cells were 60%
confluent, Myod1 was induced with 200 ng/ml doxycycline (Sigma) in GM for 24 h
and cells were collected for the GM point. When cells were 95–100% confluent,
Myod1 was induced with 200 ng/ml doxycycline (Sigma) in GM for 24 h and then
cells were differentiated in EMEM supplemented with 2% horse serum (Gibco), 1%
ITS (Sigma), and 200 ng/ml doxycycline for 3 days for the DM time point. Media
with doxycycline was refreshed every 2 days.
Luciferase reporter assay. The Fam3a regulatory region (−3000 to +100 bp) was
cloned into a pGL3 Luciferase plasmid (Fam3a-Luc). The following vectors were
used: Fam3a-Luc, pRL Renilla Luciferase Control Reporter Vector (Promega),
pcDNA3-Stat366, and pcDNA3-myc-MyoD41. HEK293 cells were transfected with
jetPRIME (cat.#114-07, Polyplus transfection) following the manufacturer’s
instructions. Luciferase and Renilla activities were measured 48 h after transfection
using the Dual Luciferase Reporter Assay System (cat.#E1910 Promega) following
the manufacturer’s instructions.
Gene expression analysis. RNA was extracted from cells using the Qiagen miR-
Neasy Micro Kit (cat.#217084, Qiagen) following the manufacturer’s protocol. Total
RNA was quantified with a QubitTM 3 Fluorometer (cat.#Q33216, Thermo Scientific).
First-strand cDNA was synthesized from total RNA using the SuperScript™ VILO™
cDNA Synthesis Kit (cat.#11754050, Invitrogen) following the manufacturer’s
instructions. cDNA was used in qPCR using the LightCycler® 96 Instrument. qPCR
reactions consisted of Power SYBR™ Green PCR Master Mix (cat.# 4367659, Life
Technologies), 250 nM forward and reverse primers, and 0.5 ng of cDNA. All mea-
surements were normalized to Rplp0 expression using the 2−δΔCT method. The
sequences of the primers used are in Supplementary Table 1.
Western blotting. Total protein extracts for western blot analyses were obtained
by homogenizing C2C12 cells in RIPA buffer (50 mM Tris-HCl pH= 7.4, 150 mM
NaCl, 1 mM EDTA, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS)) supplemented with protease inhibitors (cat.#11836153001, Sigma)
and phosphatase inhibitors (cat.#4906837001, Sigma) cocktails. Cell debris was
removed by centrifugation at 700 × g for 10 min and 4 °C and collecting the
supernatant. Protein concentration was determined using the Pierce™ BCA Protein
Assay Kit (cat.#23225, Thermo Scientific). Total protein extracts (20 µg) were
resolved in NuPAGE™ 4–12% Bis-Tris Protein Gels (cat.#NPO335BOX, Invitrogen)
by electrophoresis and then transferred to polyvinylidene difluoride membranes
(cat.#1620177, BioRad). After the transference, membranes were blocked with 1×
PBS and 0.1% Tween-20 (PBST) with 5% w/v non-fat milk at RT for 1 h, followed
by an O/N incubation with the diluted antibodies in blocking buffer at 4 °C with
gentle shaking. After washing with PBST, membranes were incubated at RT for 1 h
with a goat polyclonal anti-mouse IgG secondary antibody conjugated to horse-
radish peroxidase (cat.#1705047, BioRad). Finally, proteins were detected by
enhanced chemiluminescence (Pierce™ ECL Western Blotting Substrate, cat.
#32106, Thermo Scientific) followed by exposure to film. The following primary
antibodies were used: mouse anti-beta actin (cat.#ab20272, Abcam, 1/1000), mouse
anti-Flag (cat.#F3165, Sigma, 1/1000), and total OXPHOS Rodent WB antibody
cocktail (cat.#ab110413, Abcam, 1/1000).
For cell culture media western blot, C2C12 cells were cultured in media without
serum for 30 h. After incubation, the media was centrifuged at 3200 × g for 10 min
and 4 °C and the supernatant was collected. Then the supernatant was placed in the
Amicon® Ultra-2 centrifugal filter units (cat.#Z740164, Sigma) and concentrated
following the manufacturer’s instructions. After concentrating the media, samples
were resolved as described above.
Unprocessed images for western blots included in this manuscript are available
in Supplementary Fig. 9.
C2C12 myotubes' ChIP-seq analysis. ChIP-seq data for MyoD binding in
C2C12-derived myotubes was retrieved from SRA with accession number
SRX32869140. Reads were aligned to the UCSC mm10 build of the mouse genome
using Bowtie (v 0.12.7)67 with parameters -S -t -a -m 1 –best –strata –chunkmbs
200 and filtered with BEDtools (v2.26.0)68 according to the original publication.
Alignments were converted to bigwig format with RSeQC (v2.6.3)69 and visualized
in IGV (v2.3.98)70.
Chromatin immunoprecipitation. C2C12 myoblasts were crosslinked with 1%
formaldehyde in TBS for 15 min at RT. Formaldehyde was quenched by 0.125 mM
Glycine for 5 min at RT. Crosslinked cells were quickly washed with cold TBS, and
collected in cold TBS containing 1 mM phenylmethanesulfonylfluoride (PMSF; cat.
#93482, Sigma), protease inhibitors (cat.#11836153001, Sigma), and phosphatase
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inhibitors (cat.#4906837001, Sigma). After centrifugation at 400 × g for 8 min and
4 °C, cell pellets were resuspended in ChIP lysis buffer containing 50 mM Tris-HCl
pH= 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% SDS, 0.5% NP-40, 1 mM PMSF and
protease and phosphatase inhibitors. Chromatin was sheared to an average DNA
fragment length of 500 bp using Misonix3000 sonicator. Cell lysates were diluted
five times with the ChIP lysis buffer lacking SDS to a final concentration of 0.1%
SDS. Samples were centrifuged and the DNA concentration of soluble chromatin
was determined with a QubitTM 3 Fluorometer (cat.#Q33216, Thermo Scientific).
Thirty μg of DNA was used for immunoprecipitation with 5 μg of anti-Stat3
antibody (cat.#sc-482, Santa Cruz), anti-H3K27Ac antibody (cat.#39133, Active
Motif), and an unspecific normal rabbit IgG as a control (cat.#sc-2027, Santa Cruz).
After O/N incubation of the chromatin with the antibodies at 4 °C, the immuno-
complexes were captured with 50 μl of Protein A magnetic beads (cat.#10001D,
Invitrogen) (beads were pre-blocked with 5% IgG-free bovine serum albumin (cat.
#001-000-161, Jackson ImmunoResearch Laboratories)) for further 4 h at 4 °C.
Protein A-bound immunocomplexes were washed four times with buffer con-
taining 50 mM Tris-HCl pH= 8.0, 150 mM NaCl, 5 mM EDTA, 0.1% SDS, 1%
NP-40, 0.5% Sodium Deoxycholate, 1 mM PMSF, and protease and phosphatase
inhibitors cocktails, followed by one wash with a buffer containing 100 mM Tris-
HCl pH= 8.0, 250 mM LiCl, 5 mM EDTA, 1% NP-40, 1% Sodium Deoxycholate,
and protease and phosphatase inhibitor cocktails. After one final wash with TE
buffer, immunocomplexes were eluted from the beads and crosslinking was
reversed by incubation for 5 h at 65 °C (800 rpm shaking) with TE buffer con-
taining 1% SDS. After 0.2 mg/ml Proteinase K (cat.#P8107S, New England Bio-
Labs) treatment of samples, DNA from immunoprecipitated samples as well as
DNA from 10% input was purified by phenol and chloroform extraction and using
the QIAquick PCR Purification Kit (cat.#28106, Qiagen) following the manu-
facturer’s instructions. In all, 1/30 of the purified DNA was analyzed by qPCR
using the Power SYBR™ Green PCR Master Mix (cat.#4367659, Life Technologies).
Primers used are listed in Supplementary Table 1. The ChIP signal was evaluated
by calculating the amount of immunoprecipitated DNA relative to the input DNA
(percentage of input) and relative to control conditions.
IMR90 MyoD ChIP-seq. Cells were fixed in 1% formaldehyde in PBS for 15 min at
RT. Formaldehyde was then quenched with 125 mM Glycine for 5 min at RT. Cells
were washed in PBS and harvested in PBS supplemented with 1 mM PMSF and
protease inhibitors. Dry cell pellet was stored at −80 °C. Nuclei were then extracted
and then lysed in lysis buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5
mM EDTA, pH 8.0, 0.5% SDS, 0.5% NP-40, 1 mM PMSF, and a protease inhibitor.
Chromatin was sheared with sonicator (ColeParmer, Misonix 3000) to an average
DNA fragment length of 200–500 bp. Chromatin was then diluted five times in
lysis buffer without SDS. DNA amount was measured with the Qubit (Invitrogen
Q32854). DNA was immunoprecipitated with 2 μg of rabbit anti-Myod1 (cat.#sc-
760, Santa Cruz) O/N at 4 C. The immunocomplexes were captured with protein A
magnetic beads (Life Technologies) for 3–4 h at 4 °C. After four washes with buffer
containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, pH 8.0, 0.1%
SDS, 1% NP-40, and 0.5% sodium deoxycholate, one wash with a buffer containing
250 mM LiCl, 100 mM NaCl, 5 mM EDTA, pH 8.0, 1% NP-40, and 1% sodium
deoxycholate, and two washes with TE buffer (10 mM Tris-HCl pH= 8, 1 mM
EDTA), chromatin was then eluted and decrosslinked with 1% SDS in TE O/N at
65 °C 600 RPM rotation. Also, the input is decrosslinked with 1% SDS in TE O/N
at 65 °C 600 RPM rotation. After 2-h digestion at 37 °C with 0.2 mg/ml Proteinase
K, DNA was extracted with phenol/chloroform and ethanol precipitated O/N at
−20 °C. Prior to sequencing, DNA was then suspended in mQ water. The DNA
was then analyzed by qPCR calculating the amount of immunoprecipitated DNA
relative to the input DNA (percentage of input).
For analysis, read quality was determined using FASTQC. Reads were mapped
using bowtie2-2.0.5/bowtie2 to the female Homo sapiens hg19 genome with
options: –very-sensitive-local. Over 85% of the reads successfully mapped.
Duplicate reads were removed using samtools1.3. Peaks were called using macs2
2.1.1.20160309 with q value < 0.01. Reads were extended based on the fragment size
predicted with macs2.
Seahorse Cell Mito Stress assay. OCR and ECAR of cultured MuSCs were
measured with the Seahorse XFp Analyzer following the manufacturer’s instruc-
tions. Briefly, freshly isolated MuSCs were plated at a density of 10,000 cells/well
(cell amount was optimized to obtain reliable measurements and minimize
variability) and cultured 3 days in GM. The day of the assay, GM was substituted
with Seahorse Base XF Base Medium (cat.#102353-100, Seahorse Biosciences)
supplemented with Glucose (10 mM) and L-Glutamine (2 mM) (pH= 7.4). Cells
were then equilibrated in a non-CO2 incubator (37 °C) for 40–60 min before
running the Seahorse XFp Cell Mito Stress Test. The different compounds
were serially injected to obtain a final concentration in the wells of: 1 μM Oligo-
mycin A (cat.#75351, Sigma), 2.5 μM FCCP (cat.#2920, Sigma), 2 μM Rotenone
(cat.#R8875, Sigma), and 2 μM Antimycin A (cat.#A8674, Sigma). After the assay,
cells were fixed as previously described and nuclei stained using Hoechst 33342
(cat.#H3570, Invitrogen). ImageJ was used to quantify nuclei number for data
normalization.
Quantification and statistical analysis. Data are represented as mean ± SEM. The
investigators were not blinded to allocation during experiments or to mouse
genotypes. Sample size was chosen based on literature and variability observed in
previous experience in the laboratory. Comparisons between groups used the
Student’s t test assuming two-tailed distributions with an alpha level of 0.05. For
ChIP studies, comparisons between groups used the Student’s t test assuming one-
tailed distributions with an alpha level of 0.05. Comparisons between the Pearson’s
correlation coefficients were performed using one-way analysis of variance
(ANOVA). Comparisons between the OCR curves were performed using ordinary
two-way ANOVA. Statistical tests were performed using GraphPad Prism 7 or
Microsoft Excel for Macintosh.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the article and its supplementary information files or from the corresponding author
upon reasonable request. FASTQ files from the RNA-seq performed on freshly isolated
MuSCs from Pax7-CreER;Stat3f/f mice described in this paper have been deposited in the
Sequence Read Archive (SRA) database under accession code PRJNA510443. Public
MyoD ChIP-seq data from C2C12 myotubes were downloaded from GEO under the
code GSM1197185. Raw data files for the MyoD ChIP-seq from IMR90 human cells have
been deposited in the SRA database under accession code PRJNA526256. Processed data
for the MyoD ChIP-seq from IMR90 human cells have been deposited in GEO under the
accession code GSE128527. A reporting summary for this article is available as a
Supplementary Information file.
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